FDA Awards Fast-track Status to Sangamo’s Investigational Gene Therapy SB-525 for Hemophila A

FDA Awards Fast-track Status to Sangamo’s Investigational Gene Therapy SB-525 for Hemophila A
0
(0)

The U.S. Food and Drug Administration (FDA) has granted fast-track status to SB-525, a clinical gene therapy for hemophilia A developed by Sangamo Therapeutics in partnership with Pfizer.

SB-525 delivers a human factor VIII cDNA construct and synthetic liver-specific promoter to the cell’s nucleus by using recombinant adeno-associated virus (rAAV). The drug — created specifically as a single-time treatment — provides a continuous expression of factor VIII protein and works by replacing a defective gene with a functioning copy of that gene.

The genetic material can be delivered in a number of ways but the most common option is using a viral vector, like rAAV. Gene therapy could potentially transform the treatment of hemophilia A patients, as it offers a highly targeted dose that addresses the root cause of the disease.

“We believe SB-525 has the potential to be a best-in-class therapy that may provide patients with stable and durable levels of factor VIII protein with a single administration treatment,” Dr. Mikael Dolsten, Pfizer’s president of worldwide research and development at Pfizer, said in announcing the global agreement.

The FDA’s fast-track designation will speed up SB-525’s development and expedite its review process of a new drug. Sangamo had already received the agency’s orphan drug designation for SB-525 earlier this month. In addition, the FDA has approved Sangamo’s application for investigational new drug status. A Phase 1/2 clinical trial (NCT03061201) evaluating the gene therapy in adults with hemophilia A will likely start enrolling patients soon, with data expected in late 2017 or early 2018.

Under the agreement, Sangamo will receive an upfront payment from Pfizer to conduct the Phase 1/2 upcoming trial. Pfizer will be responsible for all subsequent research, development and commercialization activities.

“Early data shows that we may be entering a new era in treating hemophilia — not by simply replacing the missing factor up to a couple of times a week, but with a single treatment providing a correct version of the gene that may then produce curative levels of factor for life,” Greg LaRosa, who leads Pfizer’s Rare Disease Research Unit, said in a dedicated article.

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • cell therapy study
  • acquired hemophilia A treatment
  • hemophilia services for members
  • uniQure new patents

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This